The challenges associated with managing multiple myeloma patients on immunotherapy
Ignacio Melero Bermejo
How can MRD and disease be assessed in routine practice?
Daratumumab: no evidence of disease after treatment?
Blinatumomab for treating ALL
CTL019 in pediatric and young adult relapsed/refractory acute lymphoblastic leukemia (ALL) patients